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METHODOLOGY ARTICLE

Optimization algorithms for functional
deimmunization of therapeutic proteins
Methodology article

Andrew S Parker1, Wei Zheng1, Karl E Griswold*1,2 and Chris Bailey-Kellogg*1

Abstract
Background: To develop protein therapeutics from exogenous sources, it is necessary to mitigate the risks of eliciting
an anti-biotherapeutic immune response. A key aspect of the response is the recognition and surface display by
antigen-presenting cells of epitopes, short peptide fragments derived from the foreign protein. Thus, developing
minimal-epitope variants represents a powerful approach to deimmunizing protein therapeutics. Critically, mutations
selected to reduce immunogenicity must not interfere with the protein's therapeutic activity.
Results: This paper develops methods to improve the likelihood of simultaneously reducing the anti-biotherapeutic
immune response while maintaining therapeutic activity. A dynamic programming approach identifies optimal and
near-optimal sets of conservative point mutations to minimize the occurrence of predicted T-cell epitopes in a target
protein. In contrast with existing methods, those described here integrate analysis of immunogenicity and stability/
activity, are broadly applicable to any protein class, guarantee global optimality, and provide sufficient flexibility for
users to limit the total number of mutations and target MHC alleles of interest. The input is simply the primary amino
acid sequence of the therapeutic candidate, although crystal structures and protein family sequence alignments may
also be input when available. The output is a scored list of sets of point mutations predicted to reduce the protein's
immunogenicity while maintaining structure and function. We demonstrate the effectiveness of our approach in a
number of case study applications, showing that, in general, our best variants are predicted to be better than those
produced by previous deimmunization efforts in terms of either immunogenicity or stability, or both factors.
Conclusions: By developing global optimization algorithms leveraging well-established immunogenicity and stability
prediction techniques, we provide the protein engineer with a mechanism for exploring the favorable sequence space
near a targeted protein therapeutic. Our mechanism not only helps identify designs more likely to be effective, but also
provides insights into the interrelated implications of design choices.
Background
The majority of all therapeutic proteins elicit an anti-biotherapeutic immune response (aBIR) in human patients
receiving treatment [1]. The clinical effects of such a
response may include various rapidly manifested anaphylactic responses, a reduction of therapeutic efficacy, and
in rare cases cross-reactivity of anti-drug antibodies with
endogenous patient proteins resulting in a form of
induced autoimmunity [2]. Wide concern over these
issues has focused biopharmaceutical researchers on the
immunogenicity of protein therapeutics, and has driven
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the search for strategies to detect, assess, and ameliorate
potentially deleterious immune responses [3-5].
While there exists a variety of factors that influence a
protein therapeutic's immunogenicity [6,7], we focus here
on the effect of a protein's origins. Specifically, nonhuman proteins exhibit a disproportionately high frequency of immunogenicity in humans as a result of the
classical immune response [8]. In contrast, proteins of
human origin are more likely to be recognized as "self," or
to meet the "criteria of continuity" [9]. The goal is thus to
engineer variants of the foreign protein that also are recognized as "self." For therapeutic antibodies, whose structure and function are well understood, immunogenicity
reduction may be realized by rational grafting of key
functional residues from an exogenous therapeutic antibody onto a human antibody framework [10-14]. The
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resulting chimeric antibody maintains the binding specificity and affinity of the exogenous therapeutic candidate,
but the majority of the protein is comprised of humanderived amino acid sequences, thereby reducing the propensity for aBIR. The prevalence of chimeric and humanized antibodies among FDA approved therapeutics [15]
as well as a detailed meta-analysis [16] provide overwhelming evidence for the efficacy of this approach as a
whole. However, there remains a considerable empirical,
trial-and-error component, even in "rational" approaches
[17]. Rational grafting techniques require a precise
knowledge of structure-function relationships, as well as
a modular structure common to the exogenous therapeutic candidate and a homologous human protein. With the
advanced state of knowledge for immunoglobulin proteins, therapeutic antibodies inherently satisfy these prerequisites. However, exogenous enzymes, signaling
peptides, and other classes of non-human proteins represent a potentially massive pool of biotherapeutic agents.
To effectively tap this reservoir of next generation drugs,
more advanced deimmunization strategies are required
to address the fact that many of these candidates do not
possess common modular structures and frequently have
no homologous human counterpart.
One alternative to humanization by rational grafting is
the identification and modification of immunogenic peptide fragments of a protein, or T-cell epitopes, that drive
the aBIR. These peptides are derived from proteolytic
processing of protein that has been internalized by antigen presenting cells (Trombetta and Mellman [18] provide a detailed review). The peptide fragments are bound
within the groove of type II major histocompatibility
complex proteins (MHC II), which are then transported
to the surface of the immune cell where the peptideMHC II complex is displayed to the extracellular environment. Should the displayed peptides constitute immunogenic sequences, they will form ternary peptide-MHC IIT-cell receptor complexes with surface receptors of cognate white blood cells. The resulting signaling cascade
leads to a coordinated immune response against the
offending protein. To avoid such a response, it is sometimes possible to identify the most immunogenic peptide
fragments of a candidate protein, and to subsequently
mutagenize one or more of the corresponding residues so
as to disrupt the peptide fragment's capacity to complex
with the MHC II and/or T-cell receptors. This process
has been successfully applied to numerous therapeutic
candidates including staphylokinase [19], factor VIII [20],
and a β-lactamase [21]. Deimmunization by epitope deletion suffers from the limitation of being exceptionally
time and resource intensive. Traditionally, the approach
entails synthesizing and testing the immunogenicity of
large panels of peptides from the native protein, performing alanine scanning mutagenesis on the most immuno-
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genic fragments to pinpoint critical MHC II binding
residues, incorporating deimmunizing mutations into the
full length protein, and finally testing the functionality
and immunogenicity of the engineered protein variants,
only a small fraction of which are likely to retain high
activity and/or constitute globally deimmunized candidates. More advanced implementations of this strategy
exchange functionally relevant mutations for alanine
mutations, but only late in the experimental cycle.
Computational methods have been employed to aid the
identification of mutations that can effectively eliminate
MHC II binding. Often computational analyses are performed on only a small subpopulation of peptides that
have been preselected from a much larger pool of possibilities [22,23]. These approaches also typically focus on a
minimal set of only the most immunogenic peptides (typically 1-3 peptides), and therefore cannot be guaranteed
to provide globally optimal sequences. Alternatively,
numerous computational tools have been developed for
immunogenicity prediction for an entire protein, based
on its amino acid sequence [24], and the efficacies of several alternative methods have been evaluated in head-tohead comparisons [25,26]. Some such algorithms have
been used to identify immunogenic peptides in practical
biotherapeutics [27,28]; our goal is to integrate such
immunogenicity analyses within optimization algorithms that reduce predicted immunogenicity while
accounting for structural and functional consequences.
In order to address the shortcomings of earlier
approaches, this paper presents a novel protein design
method in which protein sequences are computationally
optimized to produce variants that are more likely to
exhibit both low inherent immunogenicity and high level
functionality. These are two competing concerns - mutations introduced to reduce immunogenicity may produce
unstable or inactive proteins. We establish as our primary
optimization objective reduction of immunogenicity,
according to predicted T-cell epitopes within the
sequence [25]. In order to also address the concern of stability/activity, we identify for each residue position those
mutations that are deemed acceptable according to
sequence and/or structure-based analyses. A dynamic
programming approach then finds globally optimal and
near-optimal sets of these acceptable mutations that minimize the occurrence of predicted epitopes.
Our methods provide a number of significant extensions to the state of the art. They are not limited to deimmunization of antibodies (as are simple rational grafting
techniques), but can also be applied in engineering
immunotolerant versions of more complex proteins, such
as therapeutic enzymes. Our approach seamlessly integrates immunogenic peptide identification, mutagenic
deimmunization, and functional/structural analysis of
potential mutations, employing well-established and
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effective tools for prediction of epitopes and for evaluation of stability changes. Our dynamic programmingbased algorithms are guaranteed to find globally optimal
sets of mutations, avoiding the pitfall of making a mutation to mitigate one epitope but inadvertently introducing a new overlapping epitope. We provide the protein
engineer with flexibility in setting a desired threshold for
immunogenicity, limiting the number of mutations to
consider, and in targeting specific MHC alleles. Finally, in
contrast to traditional experimental and computational
techniques, our methods preferentially guide mutations
to the most promiscuous immunogenic amino acids, i.e.,
those that are elements of two or more overlapping
immunogenic peptides (Fig. 1).
We apply our methods to optimize variants of several
different protein therapeutics that have previously been
targeted for deimmunization by other approaches. We
characterize the space of sequences near these targets,
identifying variants that are predicted to be less immunogenic than wild-type but still stable, i.e., deleting some
predicted epitopes while using only conservative substitutions. We find a number of variants that, in comparison
to earlier designs, contain fewer predicted epitopes for a
given number of substitutions, or, viewed the other way,
use fewer substitutions to delete a similar number of
epitopes. Our approach targets many of the same immunogenic regions as identified by experimental studies,
even when not specifically focused. Furthermore, by
restricting substitutions to be relatively conservative (as

assessed under several different models), our variants are
likely to maintain greater thermodynamic stability.

Methods
Our overall goal is to select, from the mutations deemed
acceptable, a set that efficiently reduces the occurrence of
predicted T-cell epitopes. We now formalize this problem; Fig. 1 illustrates.
Problem 1 (Deimmunization) Given a protein
sequence S of length n, determine a variant S' minimizing
n −8

∑i =1 e(S′i..i +8 ) , such that ?i: S'[i] ∈ M(i), where

• e : A9 T [0, 1] returns the epitope score for a peptide
(we assume a 9-mer; see below) in the range of 0 to 1,
where lower is better
• M : {1, 2, ..., n} T 2A provides the allowed residues,
indicating which amino acids (including at least the
wild-type) may be considered at each residue position
Here and throughout, we use A = {A,C,...,Y} for the
set of amino acids; sequences are 1-indexed; and the
notation Xi..j indicates the substring of X from position i
to j, inclusive.
A number of experimentally-validated bioinformatics
tools exist to predict immunogenicity (as encoded in e)
and changes in stability (M). Our current implementation
supports several state-of-the-art tools [29,30], but is
modular and can readily support others [31-33].
Immunogenicity evaluation
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Figure 1 Deimmunization overview. We employ T-cell epitope predictors to score each 9-mer peptide for potential immunogenicity. In
this example (staphylokinase residues 71-87; see the Results section),
four peptides are deemed immunogenic, as they are predicted to be
recognized by sever-al of the 8 most representative MHC II alleles. We
employ sequence and structure analysis to identify for each position
which residues are acceptable; only a few examples are shown. Our algorithms select a specified number of mutations (here two mutations,
underlined in the variant) from the acceptable ones, so as to minimize
the resulting epitope score. Note that a single substitution at a "promiscuous" amino acid can reduce recognition of multiple overlapping
epitopes, and need not be at the so-called "anchor" position.
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T-cell epitope predictors encapsulate the underlying specific recognition of an epitope by an MHC II protein. We
focus here on the human leukocyte antigen group DR
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Figure 2 Possible epitopes. Number of 9-mer peptides (out of 209
possible) recognized by exactly the number of the eight common alleles we use for epitope scoring, relative to a 10% threshold (see text).
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(HLA-DR) of MHC II proteins, since they are the predominant isotype. HLA-DR proteins have a recognition
groove whose pockets form energetically favorable interactions with specific side-chains of peptides approximately 9 residues in length. Numerous methods are
available for epitope prediction, and they have been
shown to be predictive of immunogenicity [25]. For the
results, we employ two quite different and complementary methods.
ProPred

Sturniolo et al. [34] experimentally measured the binding
affinity between individual residues and individual pockets of the MHC II binding groove on a limited set of
alleles. They then created binding profiles for untested
alleles through sequence and structure alignment with
tested alleles. In this "pocket profile" method, TEPITOPE,
the sum of position-specific weights for each residue in a
9-mer provides a score that is compared against a threshold to determine whether or not the peptide is in a given
percentile of the best-recognized peptides. The approach
was experimentally validated by comparing its predictions against HLA-DR selected and nonselected peptide
repertoires; up to 80% of the selected peptides were correctly predicted at a threshold that yielded < 5% false positives. Singh and Raghava then built a tool, ProPred, to
expand the scope of TEPITOPE and make it more easily
accessible and applicable [29]. In a recent independent
evaluation [25], ProPred did quite well in epitope prediction, achieving an average 0.73 area under the curve
(AUC) across 14 different alleles. ProPred has also been
successfully employed in a number of different studies;
e.g., it has recently helped identify antigenic sites on a
mosquito midgut glycoprotein, immunoreactive peptides
in prostatic acid phosphatase, and promiscuous T-cell
epitopes of three major secreted antigens of Mycobacterium tuberculosis [35-37]. In all three of these examples,
ProPred facilitated the rapid identification of potential
vaccine targets that were then experimentally characterized in detail. In our case study of Erythropoeitin (see
Results), we found a quite striking match between ProPred predictions and published ELISPOT assay immunogenicity results.
SMM-align

Nielsen et al. [30] pursued a different approach to epitope
prediction, developing the SMM-align method by applying machine learning techniques to large curated databases of experimentally validated epitopes: the Immune
Epitope Database IEDB [38] and SYFPEITHI [39]. While
ProPred uses data from single residues binding to single
MHC II pockets, SMM-align uses data from whole peptides. Furthermore, while ProPred is based on sequence
and structure alignment, SMM-align is uses Gibbs sam-
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pling and a regulated least squares regression to develop
position specific scoring matrices that predict the binding
affinity between an epitope and MHC II allele. In the
independent evaluation mentioned above [25], SMMalign also achieved a mean 0.73 AUC (SMM-align and
ProPred were the top two methods).
While there are over 50 different HLA-DR alleles, we
have focused on 8 common alleles (DRB1*0101,
DRB1*0301, DRB1*0401, DRB1*0701, DRB1*0801,
DRB1*1101, DRB1*1301, and DRB1*1501) that represent
the majority of human populations world-wide [40]. Thus
our epitope score is the fraction of these 8 alleles predicted to recognize a peptide. In order to evaluate the
potential for finding an epitope, we scored each of the 209
possible 9-mer peptides under ProPred at a 10% threshold. We found that 1.4 · 1011 (26.63%) are predicted to be
recognized by one or more alleles, including 5.7 ·
109(1.12%) by all 8 alleles; see Fig. 2 for a complete histogram.
Stability evaluation

Evaluating the effects of mutations on a protein's stability
and activity is at the heart of all rational protein engineering techniques. For the results, we consider three different methods using different sources of information to
determine acceptable residues likely to maintain wildtype qualities.
BLOSUM

Given sequence alone, standard substitution tables such
as BLOSUM [41] can evaluate the overall acceptability of
a mutation, according to substitutions in sets of natural
sequences. We compute a "relative" BLOSUM-62 score the difference between the wild-type/wild-type score
(diagonal) and the wild-type/mutant score. We obtain a
reasonably conservative set of acceptable residues by only
taking those with score differences of at most 4.
Conservation

A set of sequences related to the target protein reveals
which positions are highly conserved, and to which
amino acid(s), vs. which are more variable. In turn, this is
indicative of which residues are riskier to mutate and
which ones are safer. The utility of sequence alignments
in engineering thermostablilized and functional protein
variants has been proven in numerous experimental studies [42-46]. We use a multiple sequence alignment and
phylogenetic tree to compute position-specific amino
acid frequencies in a family. To avoid over-counting
highly-related sequences, we weight sequences using a
bottom-up tree-based algorithm [47]. The weighted position-specific score for amino acid a at position i, according to a multiple sequence alignment F of sequences s
with (non-normalized) weights ws is then:
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⎞
⎟⎟
⎠

(1)

We permit residues such that ϕi, a exceeds a user-specified threshold, defaulting to -log 0.05 (i.e., 5% weighted
frequency)
FoldX

When a structure is available, we employ the FoldX ΔΔG°
predictor [48] to evaluate the change in free energy for
each possible substitution. FoldX was demonstrated to
achieve of 0.83 correlation between predicted and experimental ΔΔG° over 95% of a database after outlier
removal. FoldX has since been successfully used to aid
protein design, e.g., for custom DNA kinases and potential anticancer drugs [49,50]. It is important to note that
our method does not need precise ΔΔG° prediction, but
only an indication of whether a possible substitution is
relatively "safe" (destabilizing by at most a little bit). We
allow those residues whose predicted ΔΔG° values are at
most a user-specified threshold, defaulting to 0.25 kcal/
mol, more than the wild-type value (i.e., the mutant is
nearly as good as, or even slightly better than, the wildtype).
Our problem specification treats substitutions independently of each other. While this is certainly a simplification, as residue interactions do affect stability and
activity, it enables us to more quickly generate a number
of solutions that are optimal (or near-optimal) with
respect to epitope score. These solutions can then be subjected to more expensive analyses for non-additive
effects.
Dynamic programming algorithms

Given immunogenicity and stability predictions, represented in an epitope score e and set of allowed residues
M, our goal (Problem 1) is to choose a set of mutations to
minimize the total epitope score. In order to solve this
problem by dynamic programming, let us define T [i, X]
as the best possible total epitope score for the prefix of S
ending at position i, such that the last 8 amino acids form
the string X. T can be defined recursively:
(2)
T[8, X] = 0
T[i, X] = min (T[i − 1, a ⋅ X 1..7 ] + e(a ⋅ X )), i > 8
a∈M(i −8)

(3)
where · represents concatenation.
Optimal substructure holds: the best score ending at
some position with some string must extend the best
score ending at the previous position with a compatible
string. Thus we can solve the recurrence by dynamic programming. Ultimately we want to find the minimum

value in the last column (i.e., minXT[|S|, X]), and trace
back to reconstruct the sequence. One small note of practical importance: when there is a tie for the minimum in
Eq. 3, we should of course keep the wild-type amino acid.
The calculation for each cell requires constant time,
and in the worst case there are n · 208 cells. However, in
practice we only need to fill in the entries that use allowed
substitutions; if these are reasonably conservative, the
table is much smaller. In the BLOSUM-based approach
described above, there are an average of 3.2 amino acids
to consider for each position. The Results section provides position-by-position details for a specific protein,
using BLOSUM, conservation, and FoldX.
In order to restrict the total number of substitutions
made, an additional column can be added to the dynamic
programming table. Now define R[i, X, s] as the best possible total epitope score for the prefix of S ending at position i, such that the last 8 amino acids form the string X,
and that exactly s substitutions have been made from S. R
can be defined recursively:

∑

8
⎧
I{X[i] = S[i]}
⎪ 0 if s =
R[8, X , s] = ⎨
i =1
⎪⎩ ∞ otherwise

(4)

R[i, X , s] = min (R[i − 1, a ⋅ X 1..7 , s − I{X[8] = S[i + 7]}] + e(a ⋅ X )), i > 8
a∈M(i −8)

where I{} is the indicator function, returning 1 if the
predicate is true and 0 if it is false. Here we ensure that
the s index of R counts the total number of substitutions,
starting in the base case with the number in the N-terminal 8-mer, and then in the recursive case adding 1 iff the
most C-terminal residue of X is different from the corresponding wild-type residue. The extension only affects

Number of Legal Substitutions

f i ,a

⎛ ∑ s∈F : s[i]= a w s
= − log ⎜
⎜
∑ s∈F w s
⎝
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Figure 3 Position-specific allowed residues in SakSTAR peptide.
Number of allowed residues for each position of SakSTAR 71-87 by
BLOSUM, conservation, and FoldX.
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the size of the table (scaled by a factor of n, unless s is
restricted a priori); the cost for computing each cell
remains constant. We can readily extend this approach to
calculate an (integer) substitution score for each mutation, using s to track the total substitution score rather
than the number of mutations.
While a standard dynamic programming backtrace
returns a single optimal solution, there may in fact be
multiple variants with the same score. It may also be beneficial to consider near-optimal variants, as it is unlikely
that our epitope score and evaluation of mutations are
perfect, and thus near-optimal variants are worth considering. Upon finding the set of optimal and near-optimal
solutions, we can subject them to further analysis, e.g., to
model the effects of multiple substitutions, or to consider
the ease of construction. Furthermore, by comparing and
contrasting the good variants, we can better assess the
robustness of a variant (do similar substitution patterns
show up among the good ones?), as well as the general
utility of a substitution (does it show up in many good
variants?).

The problem of extracting multiple optimal and nearoptimal solutions in dynamic programming has been
extensively studied, from the early days of the field [51]. It
has also received attention specifically in the bioinformatics community, as dynamic programming is at the
heart of sequence alignment (among other significant
problems). For example, Waterman and Byers [52] modified the standard dynamic programming backtracing procedure to produce near-optimal solutions, Naor and
Brutlag [53] presented an alternative approach for representing (rather than enumerating) all alignments whose
score is within a factor of optimal, and Gusfield [54]
explicitly accounted for the objective function parameters
that yield different optimal solutions.
Our current implementation employs the approach
described by Waterman and Byers [52] in order to generate multiple possible variants.
Implementation

We have implemented our method in platform-independent Java code. The program takes as input a target pro-

Table 1: SakSTAR 71-87 Peptide.
Variant

SakSTAR 71-87

wild type

TAYKEFRVVELDPSAKI

E

B

C

ΔΔG°

S

16

0

0.00

0.00

9

1 substitution
Warmerdam

......A..........

12

1

0.75

0.43

7

BLOSUM

........T........

8

0

-0.74

1.13

5

Conservation

........D........

5

1

0.72

1.90

3

FoldX

........K........

9

1

0.94

0.00

5

Warmerdam

......A..A.......

15

2

2.48

1.00

11

BLOSUM

........T.F......

5

0

0.28

3.12

2

Conservation

.....K..D........

1

2

0.51

4.14

1

FoldX

........K....T...

5

1

2.43

0.18

6

2 substitutions

3 substitutions
Warmerdam

......A..A.A.....

20

3

4.96

0.22

14

BLOSUM

...E....T.F......

3

0

0.45

3.73

1

Conservation

...D.K..D........

0

3

1.46

4.52

0

FoldX

...A....K....T...

3

2

3.44

0.08

4

Warmerdam

...Q..S..S....S..

15

2

4.37

2.12

7

BLOSUM

......QMA.F......

1

0

3.91

4.66

2

2

2

1.50

-0.30

4

4 substitutions

Conservation
FoldX

n/a
...AD...K....T...

Variants of SakSTAR 71-87 by Warmerdam et al. B1919, as well as by our dynamic programming algorithm, optimizing for ProPred and
allowing mutations according to BLOSUM, conservation, or FoldX. E: number of ProPred epitopes; B, C, and ΔΔG°: total substitution penalty
under BLOSUM, conservation, and FoldX, resp.; S: number of SMM-align epitopes.
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described above). The program outputs all tied-for-optimal and near-optimal variants up to a user-specified
limit, along with stability and immunogenicity evaluations of each variant according to the various predictors.
The software can be freely obtained for academic use
by request from the authors. A demonstration web-based
version is available at http://www.cs.dartmouth.edu/
~cbk/deimm/.

Number of Variants

250
200
150
100
50
0
0

5
10
15
20
25
Predicted Variant Epitope Score

30

Figure 4 Exhaustive 2-mutation search scores for SakSTAR peptide. Histogram of predicted epitope scores for all 2-mutation variants
of SakSTAR 71-87 under BLOSUM.

tein sequence, along with specifications of how to
evaluate stability and immunogenicity. As discussed
above, the program can evaluate stability with BLOSUM,
conservation (given the family multiple sequence alignment and phylogenetic tree), or FoldX (given the position-specific ΔΔG° values output from that program),
and immunogenicity with ProPred (at a user-specified 110% threshold) or SMM-align (at a user-specified IC50
from 50-5000). The user must indicate which methods to
employ, along with any necessary inputs (MSA and tree,
or FoldX output) and can adjust the thresholds for
acceptable stability scores (defaults are provided as

Results and Discussion
We demonstrate our approach by applying it to a number
of proteins that have been the object of previous deimmunization efforts. We explore the favorable sequence
space of these proteins by evaluating epitope score under
the ProPred method at a 10% threshold, and considering
allowed residues under one of BLOSUM, conservation, or
FoldX. We then independently assess each variant under
SMM-align for epitope score and each of the other measures for stability.
In presenting stability predictions, we separately sum
the value of each metric (BLOSUM, conservation, FoldX)
over all the chosen substitutions. This enables assessment
of a plan under different and potentially complementary
measures; developing a consensus method in the future
might yield even better results. The BLOSUM score for
each substitution is either 0 (allowed) or 1 (disallowed).
The negative-log conservation score for a substitution
ranges from roughly 0.01 to 4.61 (99% to 1% weighted frequency), with a maximum of roughly 3 (5% weighted frequency) for allowed substitutions. For FoldX, the score
for a substitution ranges from roughly -3 to 3 (negative

8

# alleles
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100
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130

Figure 5 Full-length SakSTAR variant profile. Optimized 6-substitution full-length SakSTAR variant with ProPred epitope scoring and conservationbased substitutions. x-axis: starting position of each 9-mer; y-axis: predicted number of alleles recognizing the 9-mer. Thin black bars indicate wild-type
scores and thick orange bars indicate variant scores. Note: wild-type epitope scores are always greater than or equal to corresponding variant ones;
i.e., we never introduce new epitopes. Blue ellipses indicate mutated positions (refer to Table 2).
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implies stabilizing), with a maximum of 0.25 for allowed
substitutions.
Staphylokinase (SakSTAR)

Warmerdam et al. [19] sought to deimmunize the fibrinselective thrombolytic agent staphylokinase, specifically
the SakSTAR wild-type variant derived from a lysogenic
S. aureus strain. They targeted the C3 region, spanning
residues 71-87, which was recognized by 90% of the Tcells cloned from a set of donors. Based on results from
alanine scanning mutagenesis, sets of 2-4 alanine substitutions were selected to produce new variants designed
to reduce immunogenicity.

We applied our approach to the original wild-type 7187 peptide, using the Staphylokinase/Streptokinase family (Pfam accession PF02821) for conservation statistics
and SakSTAR crystal structure (pdb id 2SAK) for FoldX
calculations. Fig. 3 shows the amount of freedom in planning, in terms of the number of allowable residues at each
position under our three evaluation methods. BLOSUM
is typically more conservative and is overall more uniform; conservation depends on the position-specific
diversity in the family; and FoldX allows more mutations
when analysis of the structure at hand indicates that they
would not be too destabilizing. On average, BLOSUM

Table 2: Full-length SakSTAR.
Variant

SakSTAR 1-136

E

B

C

ΔΔG°

S

wild type

SakSTAR

99

0

0.00

0.00

49

Warmerdam

R77A

95

1

0.75

0.43

47

BLOSUM

V27T

88

0

0.89

2.08

48

Conservation

M26D

79

1

1.15

1.89

41

FoldX

V112P

90

1

0.93

-0.03

47

1 substitution

2 substitutions
Warmerdam

R77A,E80A

98

2

2.48

1.00

51

BLOSUM

V27T,S84E

79

0

3.18

2.70

43

Conservation

M26D,V79D

68

2

1.87

3.79

35

FoldX

Y24H,V112P

82

2

1.89

0.04

43

Warmerdam

R77A,E80A,D82A

105

3

4.96

0.22

55

BLOSUM

V27T,S84E,V112A

70

0

1.98

3.16

41

Conservation

M26D,I49D,V79D

58

3

1.51

7.46

31

FoldX

Y24H,V79K,V112P

75

3

2.83

0.04

39

3 substitutions

4 substitutions
Warmerdam

K74Q,R77S,E80S,D82S

103

3

5.93

1.28

52

BLOSUM

V27T,V45A,S84E,V112A

63

0

2.36

3.98

42

Conservation

M26D,I49D,V79D,V112K

49

4

1.28

6.72

29

FoldX

Y24H,N28E,V79K,V112P

69

4

4.28

0.00

35

BLOSUM

V27T,V45A,S84E,V112A,K130E

58

0

3.12

5.41

40

Conservation

M26D,I49D,V79D,V112K,F125E

41

5

1.74

12.60

25

FoldX

Y24H,N28E,Y62R,V79K,V112P

63

5

4.37

0.12

33

BLOSUM

V27T,V45A,V79T,V89T,V112A,K130E

54

0

0.74

8.26

41

Conservation

M26D,I49D,Y62D,V79D,V112K,F125E

34

6

1.92

13.56

23

FoldX

Y24H,N28E,Y62K,V79K,S84T,V112P

58

5

5.32

0.01

34

5 substitutions

6 substitutions

Variants of the full SakSTAR protein by Warmerdam et al. [19], as well as by our dynamic programming algorithm, optimizing for ProPred and
allowing mutations according to BLOSUM, conservation, or FoldX. E: number of ProPred epitopes; B, C, and ΔΔG°: total substitution penalty under
BLOSUM, conservation, and FoldX, resp.; S: number of SMM-align epitopes.
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permits 4.2 residues per position, conservation 6.4, and
FoldX 6.9. Table 1 summarizes some of our optimized
variants, one per allowed residue predicate (BLOSUM,
conservation, and FoldX). Our objective function is the
number of ProPred-predicted epitopes, so this number
naturally decreases with the number of substitutions,
though it is worth noting that each substitution actually
deletes several predicted epitopes. Furthermore, the
independent predictor SMM-align (not part of the objective function) likewise trends downward with an increasing number of substitutions. Since ProPred was derived
from pocket profiles and sequence alignments, while

SMM-align was trained on specific experimentally identified epitopes, they provide complementary assessments
of immunogenicity, and their agreement suggests that we
are indeed likely to be deleting actual epitopes. By comparing results for the different allowed residue predicates,
we can gain insights into how best to delete these
epitopes, from a stability-preservation viewpoint. For
example, we see that V79 was chosen for the first substitution under all three approaches. With BLOSUM, the
conservative V79T was chosen; with conservation, D79
was recognized as sufficiently common in the sequence
record; and with FoldX, K79 was predicted to maintain

8

# alleles

6

4

2

0
0

71

73

75

77
79
81
peptide start position

83

85

87

71

73

75

77
79
81
peptide start position

83

85

87

8

# alleles

6

4

2

0
0

Figure 6 SakSTAR peptide with ProPred 5% and 10% thresholds. Optimized SakSTAR peptide variant with ProPred epitope scoring at 5% (top)
and 10% (bottom) thresholds. x-axis: starting position of each 9-mer; y-axis: predicted number of alleles recognizing the 9-mer. Thin black bars indicate
wild-type scores and thick orange bars indicate variant scores. Note: wild-type epitope scores are always greater than or equal to corresponding variant ones; i.e., we never introduce new epitopes. The blue ellipse indicates BLOSUM-based substitution V79T.

Parker et al. BMC Bioinformatics 2010, 11:180
http://www.biomedcentral.com/1471-2105/11/180

stability. On the other hand, the three-substitution conservation-based variant eliminates all epitopes (and of
course looks good from a conservation analysis), but
incurs a large ΔΔG° penalty relative to the solutions from
the other metrics. It is worth noting that currently only
the epitope score is the objective function (though we
could readily employ a linear combination with a substitution score), and the goal is to delete as many epitopes as
possible using substitutions allowed by a particular predicate. Thus, for example, in order to delete more epitopes,
a conservation-based design may actually end up with a
larger conservation penalty than a BLOSUM-based
design, by using less common substitutions (but ones still
meeting the weighted 0.05% frequency threshold) that are
not allowed by BLOSUM. Further insights can be gained
by considering all tied-for-optimal variants (Additional
file 1, Table S1). For example, we can identify commonly
selected mutations, e.g., V79T and V79K, and might consider variants incorporating them to be of higher quality.
Our method identifies the favorable region of the
sequence space, but a natural question is what portion of
the space is favorable. In other words, are many or most
variants likely to be good anyway? Fig. 4 shows the distribution of epitope scores for all 2-mutation variants of
SakSTAR, using all acceptable mutations according to the
BLOSUM evaluation. (Of course, with larger numbers of
mutations and longer sequence, the exhaustive approach
would not be feasible.) The figure makes clear that most
variants have scores much worse than the optimal ones
designed by our approach: the median score is 16 and
only 5 of the 1338 sequences (0.37%) achieve the optimal
score of 5. Thus experiment planning techniques are
required, as stochastic methods are unlikely to produce
high-quality variants.
Our designs show dramatic reduction in predicted Tcell epitope content (under both ProPred and SMMalign) compared to the variants chosen by Warmerdam et
al. Their variants minimally decrease, or even introduce
new predicted T-cell epitopes, due in part to limitations
in their selection of amino acids (using only alanine for
the 2- and 3-substitution variants).
While Warmerdam et al. focused effort on the C3
region, our method is able to globally optimize an entire
protein and thereby address a weakness identified in the
earlier method: the "vast majority of humans recognize
additional immunogenic SakSTAR regions" [19]. Fig. 5
profiles a 6-mutation full-protein variant identified by
our method. Notice that even though it was not specifically targeted, the C3 immunogenic region was addressed
with substitution V79D. In addition, mutations were
selected in five other regions of high predicted immunogenicity. Each mutation deletes an average of 6.5 epitopes,
overlapping the substituted position and/or for different
MHC-II alleles. Furthermore (Table 2), all substitutions
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are to amino acids with weighted frequency greater than
.05 at those positions in the staphylokinase family. Table 2
and Additional file 1, Table S2 detail a number of the fullprotein variants for different numbers of mutations.
Again the SMM-align epitope evaluation correlates very
well with the optimized ProPred score, trending downward with increasing numbers of substitutions. The different allowed residue predicates all hit the C3 region
(71-87) within the first few substitutions (again often
picking V79), but also delete epitopes in a number of
other predicted immunogenic regions (see again Fig. 5).
The designs compare favorably with the Warmerdam
designs in terms of both epitope predictors. The conservation-based variants tend to be particularly aggressive in
deleting epitopes by choosing other residues represented
in the family, but sacrifice more in predicted stability
under FoldX.
ProPred Threshold

Epitope predictors employ thresholds in deciding to label
peptides as MHC-II binders or non-binders. To illustrate
our algorithm, we have employed the "loosest" ProPred
threshold of 10%, erring on the side of predicting spurious epitopes instead of on the side of missing epitopes.
We also evaluated plans for SakSTAR based on a tighter
threshold of 5%. As expected, with the 5% threshold, ProPred predicts fewer epitopes than with the 10% threshold:
SakSTAR 71-87 has 16 predicted epitopes at 10% but only
8 at 5%. At 5% our algorithm finds completely deimmunized variants for the peptide within 4 substitutions
(Additional file 1, Table S3). The substitution V79T eliminates 75% of the epitopes predicted in the 71-87 peptide
at the 5% threshold and 50% of those predicted at the 10%
threshold (Fig. 6). For full-length SakSTAR, both thresholds predict the same regions to be immunodominant
(Fig. 5 and Additional file 1, Fig. S1). Changing the
threshold from 10% to 5% seems to evenly attenuate the
epitope signal across the protein. Of particular significance, we note that our optimization algorithm selects
exactly the same full-length 6-substitution conservationbased variant with the 5% threshold (Additional file 1,
Table S4) as it did for 10% (Table 2). The plan eliminates a
strikingly high proportion of epitopes, 66% at the 10%
threshold and 88% at 5%.
Allele Analysis

A detailed analysis of predicted SakSTAR epitopes by
binding allele shows that our 6-substitution conservation-based variant eliminates some of the epitopes predicted for each different allele (Figs. 7 and 8). At the
ProPred 5% threshold, our design eliminates all epitopes
predicted to bind to alleles HLA-DRB1*0101 and HLADRB1*1501. Total allele elimination does not occur at the
10% threshold, although in the variant, alleles 0101 and
1501 are predicted to bind only 1 and 2 epitopes, respectively. The plots further underscore the observation that
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Figure 7 Full-length SakSTAR epitope analysis by allele with ProPred 5% threshold. Optimized 6-substitution SakSTAR variant with ProPred
epitope scoring (5% threshold) and conservation-based substitutions. x-axis: sequence position; y-axis: HLA-DRB1* allele recognizing the 9-mer. Lines:
9-residue extent of epitopes in the wild-type; cross-hatched lines: epitopes remaining in the variant. Blue ellipses indicate mutated positions (refer to
Additional File 1 Table S4).



 



 
 






























Figure 8 Full-length SakSTAR epitope analysis by allele with ProPred 10% threshold. Optimized 6-substitution SakSTAR variant with ProPred
epitope scoring (10% threshold) and conservation-based substitutions. x-axis: sequence position; y-axis: HLA-DRB1* allele recognizing the 9-mer.
Lines: 9-residue extent of epitopes in the wild-type; cross-hatched lines: epitopes remaining in the variant. Blue ellipses indicate mutated positions
(refer to Table 2).
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Figure 9 Full-length Epo variant profile. Optimized 10-substitution Epo variant with ProPred epitope scoring and BLOSUM-based substitutions. xaxis: starting position of each 9-mer; y-axis: predicted number of alleles recognizing the 9-mer. Thin black bars indicate wild-type scores and thick orange bars indicate variant scores. Note: wild-type epitope scores are always greater than or equal to corresponding variant ones; i.e., we never introduce new epitopes. Blue ellipses indicate mutated positions (refer to Table 3). The line plot, from Tangri et al. [22] displays wild-type Epo antigenicity
using ELISPOT assays, with black squares giving the number of alleles bound to overlapping 15-mers.

the 5% and 10% thresholds yield similar epitope profiles
across the whole protein both by sequence and by allele.
As mentioned above, the optimal deimmunizing mutations are identical for plans under both thresholds, but a
greater percentage of predicted epitopes are eliminated at
the 5% threshold. In general, it is easier to eliminate an
epitope that lies between the 5% and 10% threshold than
one that exceeds the 10% threshold. For example, in the
5% plan, the V79T mutation eliminates 3 of 4 epitopes
beginning at residue 76, but none of these four epitopes
are eliminated at the 10% threshold.
Erythropoietin (Epo)

Tangri et al. [22] focused on two regions in the protein
therapeutic erythropoietin (Epo), residues 101-115 and
136-150, which they experimentally determined to be
immunogenic during an intensive analysis of peptide
fragments spanning the entire length of the protein. They
engineered four variants targeting the anchor residues of
identified T-cell epitopes in these regions: L102P/S164D
(named G2), T107D/S146D (G3), L102G/T107D/S146D
(G4), and L102S/T107D/S146D (G5).
We applied our methods to explore the favorable
sequence space of Epo, using the Erythropoietin/thrombopoietin family (Pfam accession PF00758) for the conservation statistics and the crystal structure of human
Epo (pdb id 1EER) for the FoldX analysis. As demonstrated above for SakSTAR, our method is not restricted
to optimizing only targeted regions, but can instead seek

to delete epitopes throughout the protein. Since both the
ProPred and SMM-align epitope predictors and Tangri et
al.'s in vitro assays showed that there are many immunogenic regions in Epo, we performed full-protein optimization, rather than restricting the allowed substitutions to
the 101-115 and 136-150 regions. Fig. 9 illustrates a 10mutation BLOSUM-based variant. The black line is an
experimentally determined immunogenicity plot from
Tangri et al. [22] and trends well with the ProPred model
of immunogenicity. Some deviations may be explained by
the difference in alleles tested (we share 6 of their alleles),
and by the fact that they analyze 15-mers at every 5 positions while we analyze 9-mers at every position. Nonetheless, the correlation is quite striking, as is the ability of
our design to target most of the highly immunogenic
regions with only a small number of substitutions. Each
substitution is quite effective, deleting an average of 6.3
epitopes.
Table 3 summarizes a number of our optimized variants, as with SakSTAR listing just one for each allowed
residue predicate (see Additional file 1, Table S5 for a full
list). The first substitution made under BLOSUM and
conservation is to R110, in the 101-115 region, while that
under FoldX is to N147, in the 136-150 region, though
neither of these regions was specifically targeted. As
more substitutions are added, other predicted epitopes
are deleted, including more in those regions. Thus our
objective function, the ProPred score, continues to
decrease; the trend is roughly the same for both the Tan-
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Table 3: Full-length Epo.
Variant

Epo 1-166

E

B

C

ΔΔG°

S

wild type

Epo

136

0

0.00

0.00

74

BLOSUM

R110Q

126

0

2.87

0.70

72

Conservation

R110G

128

1

2.81

1.87

75

FoldX

N147D

124

1

2.22

-0.33

70

Tangri G2

L102P,S146D

118

1

4.97

6.06

65

Tangri G3

T107D,S146D

121

1

4.67

1.02

62

BLOSUM

R110Q,S146D

119

0

4.92

0.92

65

Conservation

R76A,R110G

120

2

5.48

3.47

76

FoldX

F48D,N147D

115

2

5.07

-0.59

65

Tangri G4

L102G,T107D,S146D

113

2

7.59

6.09

57

Tangri G5

L102S,T107D,S146D

115

2

7.59

4.89

58

BLOSUM

R76Q,V82T,R110Q

111

0

8.91

1.78

72

Conservation

V56E,R76A,R110G

113

3

7.95

3.29

69

FoldX

F48D,V82K,N147D

108

3

6.96

-1.18

63

BLOSUM

R76Q,V82T,R110Q,S146D

104

0

10.96

2.00

65

Conservation

V56E,R76A,V82A,R110G

106

3

7.62

3.06

68

FoldX

F48D,V82E,L93E,N147D

101

4

10.01

-0.87

60

BLOSUM

S71E,R76K,V82T,R110Q,S146D

98

0

12.91

1.31

62

Conservation

V56E,R76A,V82A,L91G,R110G

101

4

10.40

4.77

66

FoldX

F48D,V82E,L93E,S146D,N147D

95

4

12.05

-0.65

57

BLOSUM

R53Q,S71D,R76K,V82T,S104D,

0

23.90

2.93

49

1 substitution

2 substitutions

3 substitutions

4 substitutions

5 substitutions

10 substitutions
73

R110Q,R143Q,S146D,R150Q,K154E
Variants of the entire Epo protein by Tangri et al. [22] as well as by our dynamic programming algorithm, optimizing for ProPred and allowing
mutations according to BLOSUM, conservation, or FoldX. E: number of ProPred epitopes; B, C, and ΔΔG°: total substitution penalty under
BLOSUM, conservation, and FoldX, resp.; S: number of SMM-align epitopes.

gri variants and ours. In some cases the independent
SMM-align score fluctuates more than others, e.g., BLOSUM alternates between using S164D or not. This observation highlights the fact that some substitutions may be
particularly good for the SMM-align score but not as
important for the ProPred objective function.
As with SakSTAR, comparison of the different predicates yields insights into positions and substitutions that
appear to be good in general; e.g., V82T under BLOSUM,
V82A under conservation, and V82E under FoldX, deleting 7, 6, and 7 epitopes respectively. Notably, none of the
V82 mutations eliminates the epitope anchored at L80 on
allele HLA-DRB*0401. Otherwise V82T and V82A elimi-

nate all of the epitopes in the region overlapping position
82. Our global optimization recognizes diminishing
returns at this area on the protein. While adding additional mutations in the region may eliminate the final
regional epitope at L80; it is only one epitope, and mutations elsewhere eliminate more epitopes.
Therapeutic Antibodies

Lazar et al. [23] introduced the concept of "human string
content," or the percent identity between peptides
derived from a test antibody sequence and corresponding
peptides taken from a multiple sequence alignment of
homologous human antibodies. We applied our methodology to anti-Her2/neu antibody 4D5, the anti-EGFR
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antibody 225, and the anti-EpCAM antibody 17-1A. At
the 16-substitution level, we are able to reduce epitope
score by about 70-90%; this compares favorably to the
previous work, which required more than four times that
many substitutions. See Additional file 1 for a more
detailed description of the case study and our results.

Other requirements: Java 1.6 or higher
License: GNU GPL
Any restrictions to use by non-academics: Please
contact the authors before non-academic use.

Conclusions
We have shown that dynamic programming can address
the problem of designing protein variants predicted to
have reduced immunogenicity while maintaining stability. Our method found a number of variants that compare
favorably to those developed in previous efforts. In many
cases, our designs delete more epitopes than previous
efforts, as measured by the ProPred pocket profile
method and independently assessed with the SMM-align
method. At the same time, the capacity of our algorithm
to integrate stability analysis with deimmunization
resulted in variants predicted to maintain greater thermodynamic stability. We further showed our optimization methods to be highly efficient, eliminating on
average over 6 epitopes per mutation. Finally, one of the
most powerful features of our methods is that we achieve
global deimmunization as opposed to targeted deletion of
a single epitope regardless of other immunogenic or functional consequences.
The algorithm guarantees that our variants are provably optimal with respect to the epitope and stability predictors, but this does not guarantee optimal properties in
vivo. Instead, our algorithm should be viewed as a way to
suggest variants worth studying experimentally. It provides a tool for the protein designer to explore the space
of designs and focus in what appears to be a beneficial
region, according to the best available predictions.
Future experimental work will focus on selection of one
or more therapeutic targets that will be subjected to an
exhaustive optimization under several mutational loads.
Based on the resulting plans, small libraries of candidate
variants will be constructed, expressed and purified,
tested for functionality, and experimentally evaluated for
immunogenic potential. Further computational work will
develop other classes of optimization algorithms for
incorporating properties not strictly local in terms of the
primary sequence, such as residues that covary in the
sequence record or form strong interactions in the threedimensional structure.

Additional file 1 Additional variants. The file includes additional variants
for SakSTAR 71-87, full-length SakSTAR, and full-length Epo, as well as an
additional case study for Abs 4D5, 225, and 17-1A.
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